FDA addresses ANDA conversion to tentative approval for patent infringement

A new Manual of Policies and Procedures (MAPP) from the US Food and Drug Administration (FDA) addresses conversion of an abbreviated new drug application’s (ANDA) status from final to tentative approval following a court order for patent infringement.